SXTC
China SXT Pharmaceuticals, Inc.
Price Chart
Latest Quote
$2.23
+0.01 (+0.45%)
Current Price
| Previous Close | $2.22 |
| Open | $2.44 |
| Day High | $2.44 |
| Day Low | $2.18 |
| Volume | 46,982 |
Stock Information
| Shares Outstanding | 4.46M |
| Total Debt | $1.20M |
| Cash Equivalents | $21.31M |
| Revenue | $1.54M |
| Net Income | $-8.87M |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Market Cap | $9.94M |
| EPS (TTM) | $-57.15 |
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $-18.31M |
| Sales | $1.54M |
| Income | $-8.87M |
| Book/sh | $26.16 |
| Cash/sh | $4.78 |
| Employees | 75 |
Financial Ratios
| Quick Ratio | 4.04 |
| Current Ratio | 4.37 |
| Debt/Eq | 5.95 |
Returns & Margins
| ROA | -18.27% |
| ROE | -50.30% |
| Gross Margin | 21.74% |
| Operating Margin | -1011.69% |
Ownership
| Insider Ownership | 0.71% |
| Institutional Ownership | 0.21% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| P/S | 6.46 |
| P/B | 0.09 |
Analyst Data
| Recommendation | none |
Technical Indicators
| SMA20 | $1.84 |
| SMA50 | $1.88 |
| SMA200 | $103.29 |
| RSI | 64.43 |
| ATR | 0.2761 |
| Shares Float | 741K |
| Short Float | 0.12% |
| Short Ratio | 0.22 |
| Volatility | 1.89 |
| Rel Volume | 0.34 |
Performance History
| Week | -1.33% |
| Month | +43.87% |
| Quarter | +49.66% |
| 6 Months | -99.09% |
| YTD | -99.15% |
| Year | -99.20% |
| 3 Years | -99.73% |
| 5 Years | -99.96% |
| 10 Years | -100.00% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-18 | $2.23 | 46,982 |
| 2026-06-17 | $2.22 | 70,800 |
| 2026-06-16 | $2.32 | 16,300 |
| 2026-06-15 | $2.35 | 86,100 |
| 2026-06-12 | $2.57 | 161,500 |
| 2026-06-11 | $2.26 | 1,156,700 |
| 2026-06-10 | $1.76 | 273,800 |
| 2026-06-09 | $1.56 | 133,400 |
| 2026-06-08 | $1.55 | 266,300 |
| 2026-06-05 | $1.44 | 64,200 |
| 2026-06-04 | $1.57 | 53,600 |
| 2026-06-03 | $1.73 | 21,200 |
| 2026-06-02 | $1.78 | 119,300 |
| 2026-06-01 | $1.68 | 110,800 |
| 2026-05-29 | $1.67 | 81,600 |
| 2026-05-28 | $1.56 | 59,800 |
| 2026-05-27 | $1.55 | 24,900 |
| 2026-05-26 | $1.67 | 28,300 |
| 2026-05-22 | $1.66 | 7,400 |
| 2026-05-21 | $1.64 | 19,100 |
| 2026-05-20 | $1.60 | 15,100 |
| 2026-05-19 | $1.55 | 5,200 |
About China SXT Pharmaceuticals, Inc.
China SXT Pharmaceuticals, Inc., a pharmaceutical company, engages in the research, development, manufacture, marketing, and sale of traditional Chinese medicine pieces (TCMP) in China. The company offers advanced, fine, and regular TCMP products, and raw medicinal material, such as SanQiFen, HongQi, SuMu, JiangXiang, CuYanHuSuo, XiaTianWu, LuXueJing, XueJie, ChaoSuanZaoRen, HongQuMi, ChuanBeiMu, HuangShuKuiHua, WuWeiZi, DingXiang, RenShen, QingGuo, JueMingZi, ShaRen, and ChenXiang. It provides its products under the Suxuantang, Hui Chun Tang, and Tong Ren Tang brands. The company serves pharmaceutical companies, chain pharmacies, and hospitals, as well as pharmaceutical distributors. China SXT Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Taizhou, China.
đ° Latest News
BC-Most Active Stocks
Associated Press Finance âĸ 2026-02-02T15:30:17ZChina SXT Pharmaceuticals Full Year 2025 Earnings: US$2.32 loss per share (vs US$28.58 loss in FY 2024)
Simply Wall St. âĸ 2025-08-02T13:55:09Z
US Market's Undiscovered Gems Featuring 3 Promising Stocks
Simply Wall St. âĸ 2025-07-31T17:33:03Z
Undiscovered Gems in the US Market for July 2025
Simply Wall St. âĸ 2025-07-31T11:33:03Z
US Undiscovered Gems with Strong Potential July 2025
Simply Wall St. âĸ 2025-07-29T17:33:16Z
US Market's Hidden Treasures Featuring Three Undiscovered Gems
Simply Wall St. âĸ 2025-07-29T11:33:13Z
Discovering US Undiscovered Gems With Strong Potential
Simply Wall St. âĸ 2025-07-28T11:33:15Z
US Undiscovered Gems with Potential for July 2025
Simply Wall St. âĸ 2025-07-25T17:32:57Z
Discovering US Market's Undiscovered Gems In July 2025
Simply Wall St. âĸ 2025-07-24T17:33:10Z
US Market's Top 3 Undiscovered Gems For Your Portfolio
Simply Wall St. âĸ 2025-07-22T17:33:24Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $1,373,480 | $1,374,526 | $1,545,408 | $1,350,638 |
| Cost Of Revenue | $1,373,480 | $1,374,526 | $1,545,408 | $1,350,638 |
| Total Revenue | $1,740,907 | $1,928,497 | $1,971,679 | $2,602,281 |
| Operating Revenue | $1,740,907 | $1,928,497 | $1,971,679 | $2,602,281 |
| Expenses | ||||
| Interest Expense | $648,221 | $544,279 | $476,776 | $36,695 |
| Total Expenses | $4,421,386 | $4,443,714 | $7,579,188 | $7,791,954 |
| Other Income Expense | $25,048 | $-39,036 | $149,513 | $-181,581 |
| Other Non Operating Income Expenses | $25,048 | $-39,036 | $149,513 | $-181,581 |
| Net Non Operating Interest Income Expense | $-648,221 | $-544,279 | $-476,776 | $-36,695 |
| Interest Expense Non Operating | $648,221 | $544,279 | $476,776 | $36,695 |
| Operating Expense | $3,047,906 | $3,069,188 | $6,033,780 | $6,441,316 |
| Selling And Marketing Expense | $289,859 | $433,566 | $387,452 | $924,538 |
| General And Administrative Expense | $2,758,047 | $2,635,622 | $5,646,328 | $5,516,778 |
| Total Other Finance Cost | - | - | $476,776 | $36,695 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-3,303,652 | $-3,098,532 | $-5,934,772 | $-5,736,095 |
| Net Interest Income | $-648,221 | $-544,279 | $-476,776 | $-36,695 |
| Normalized Income | $-3,303,652 | $-3,098,532 | $-5,934,772 | $-5,736,095 |
| Net Income From Continuing And Discontinued Operation | $-3,303,652 | $-3,098,532 | $-5,934,772 | $-5,736,095 |
| Total Operating Income As Reported | $-2,680,479 | $-2,515,217 | $-5,607,509 | $-5,189,673 |
| Net Income Common Stockholders | $-3,303,652 | $-3,098,532 | $-5,934,772 | $-5,736,095 |
| Net Income | $-3,303,652 | $-3,098,532 | $-5,934,772 | $-5,736,095 |
| Net Income Including Noncontrolling Interests | $-3,303,652 | $-3,098,532 | $-5,934,772 | $-5,736,095 |
| Net Income Continuous Operations | $-3,303,652 | $-3,098,532 | $-5,934,772 | $-5,736,095 |
| Pretax Income | $-3,303,652 | $-3,098,532 | $-5,934,772 | $-5,407,949 |
| Operating Income | $-2,680,479 | $-2,515,217 | $-5,607,509 | $-5,189,673 |
| Gross Profit | $367,427 | $553,971 | $426,271 | $1,251,643 |
| Special Income Charges | - | - | - | $0 |
| Per Share | ||||
| Diluted EPS | $-348.15 | $-1676.69 | $-15576.83 | $-85613.36 |
| Basic EPS | $-348.15 | $-1676.69 | $-15576.83 | $-85613.36 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-2,573,134 | $-2,351,006 | $-5,207,834 | $-5,051,247 |
| Reconciled Depreciation | $82,297 | $203,247 | $250,162 | $320,007 |
| EBITDA (Bullshit earnings) | $-2,573,134 | $-2,351,006 | $-5,207,834 | $-5,051,247 |
| EBIT | $-2,655,431 | $-2,554,253 | $-5,457,996 | $-5,371,254 |
| Diluted Average Shares | $9,488 | $1,848 | $381 | $67 |
| Basic Average Shares | $9,488 | $1,848 | $381 | $67 |
| Diluted NI Availto Com Stockholders | $-3,303,652 | $-3,098,532 | $-5,934,772 | $-5,736,095 |
| Tax Provision | $0 | $0 | $0 | $328,146 |
| Selling General And Administration | $3,047,906 | $3,069,188 | $6,033,780 | $6,441,316 |
| Other Gand A | $2,758,047 | $2,635,622 | $5,646,328 | $5,516,778 |
| Total Unusual Items | - | - | - | $0 |
| Total Unusual Items Excluding Goodwill | - | - | - | $0 |
Fetched: 2026-06-17
Balance Sheet (Annual)
| Metric | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $15,427,954 | $13,911,345 | $14,663,427 | $16,385,946 |
| Total Assets | $21,663,508 | $23,127,057 | $29,554,056 | $33,546,273 |
| Total Non Current Assets | $367,017 | $8,893,698 | $10,032,809 | $11,094,418 |
| Non Current Prepaid Assets | $0 | $8,309,904 | $8,736,677 | $9,464,767 |
| Goodwill And Other Intangible Assets | $11,808 | $19,101 | $27,868 | $38,762 |
| Other Intangible Assets | $11,808 | $19,101 | $27,868 | $38,762 |
| Current Assets | $21,296,491 | $14,233,359 | $19,521,247 | $22,451,855 |
| Restricted Cash | $30,413 | $6,842 | $0 | $45,297 |
| Prepaid Assets | $438,854 | $14,902 | $46,304 | $50,313 |
| Inventory | $828,053 | $794,855 | $531,254 | $1,017,527 |
| Receivables | $1,900,152 | $1,346,415 | $1,575,211 | $5,814,396 |
| Receivables Adjustments Allowances | $-466,528 | $-468,880 | $-473,237 | $0 |
| Other Receivables | $523,070 | $500,514 | $645,498 | $849,128 |
| Loans Receivable | $124,712 | $0 | $0 | $1,500,000 |
| Accounts Receivable | $1,301,335 | $1,314,781 | $1,344,569 | $3,333,178 |
| Allowance For Doubtful Accounts Receivable | $-2,082,442 | $-1,731,517 | $-1,522,739 | $-762,992 |
| Gross Accounts Receivable | $3,383,777 | $3,046,298 | $2,867,308 | $4,096,170 |
| Cash Cash Equivalents And Short Term Investments | $18,099,019 | $12,070,345 | $17,368,478 | $15,524,322 |
| Cash And Cash Equivalents | $18,099,019 | $12,070,345 | $17,368,478 | $15,524,322 |
| Accrued Interest Receivable | - | - | $0 | $81,000 |
| Notes Receivable | - | - | $0 | $35,509 |
| Non Current Deferred Assets | - | - | - | $0 |
| Non Current Deferred Taxes Assets | - | - | - | $0 |
| Other Current Assets | - | - | - | $288,936 |
| Current Deferred Assets | - | - | - | $0 |
| Debt | ||||
| Total Debt | $983,877 | $2,647,455 | $3,756,720 | $2,046,351 |
| Long Term Debt And Capital Lease Obligation | $211,683 | $294,667 | $365,823 | $0 |
| Long Term Debt | $96,264 | $117,129 | $117,862 | - |
| Current Debt And Capital Lease Obligation | $772,194 | $2,352,788 | $3,390,897 | $2,046,351 |
| Current Debt | $710,965 | $2,294,478 | $3,332,808 | $2,046,351 |
| Other Current Borrowings | $710,965 | $2,294,478 | $3,332,808 | $2,046,351 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $6,223,746 | $9,196,611 | $14,862,761 | $17,121,565 |
| Total Non Current Liabilities Net Minority Interest | $211,683 | $294,667 | $365,823 | $0 |
| Current Liabilities | $6,012,063 | $8,901,944 | $14,496,938 | $17,121,565 |
| Other Current Liabilities | $674,391 | $361,543 | $789,232 | $1,162,310 |
| Current Deferred Liabilities | $58,627 | $187,665 | $165,534 | $77,366 |
| Payables And Accrued Expenses | $4,452,966 | $5,786,377 | $10,039,324 | $14,875,075 |
| Payables | $3,348,840 | $4,560,063 | $9,089,730 | $14,028,101 |
| Other Payable | $1,159,135 | $1,180,556 | $1,403,258 | $2,682,512 |
| Total Tax Payable | $1,031,407 | $1,052,441 | $1,104,860 | $1,167,695 |
| Accounts Payable | $1,158,298 | $1,279,516 | $1,377,850 | $1,482,192 |
| Equity | ||||
| Common Stock Equity | $15,439,762 | $13,930,446 | $14,691,295 | $16,424,708 |
| Total Equity Gross Minority Interest | $15,439,762 | $13,930,446 | $14,691,295 | $16,424,708 |
| Stockholders Equity | $15,439,762 | $13,930,446 | $14,691,295 | $16,424,708 |
| Gains Losses Not Affecting Retained Earnings | $-1,075,522 | $-1,025,795 | $-197,571 | $956,142 |
| Other Equity Adjustments | $-1,075,522 | $-1,025,795 | $-197,571 | $956,142 |
| Retained Earnings | $-28,015,317 | $-24,711,665 | $-21,613,133 | $-15,688,278 |
| Other | ||||
| Ordinary Shares Number | $91,755 | $1,848 | $381 | $67 |
| Share Issued | $91,755 | $1,848 | $381 | $67 |
| Tangible Book Value | $15,427,954 | $13,911,345 | $14,663,427 | $16,385,946 |
| Invested Capital | $16,246,991 | $16,342,053 | $18,141,965 | $18,471,059 |
| Working Capital | $15,284,428 | $5,331,415 | $5,024,309 | $5,330,290 |
| Capital Lease Obligations | $176,648 | $235,848 | $306,050 | $0 |
| Total Capitalization | $15,536,026 | $14,047,575 | $14,809,157 | $16,424,708 |
| Additional Paid In Capital | $0 | $35,315,616 | $35,588,214 | $30,994,376 |
| Capital Stock | $44,530,601 | $4,352,290 | $913,785 | $162,468 |
| Common Stock | $44,530,601 | $4,352,290 | $913,785 | $162,468 |
| Long Term Capital Lease Obligation | $115,419 | $177,538 | $247,961 | $0 |
| Current Deferred Revenue | $58,627 | $187,665 | $165,534 | $77,366 |
| Current Capital Lease Obligation | $61,229 | $58,310 | $58,089 | $0 |
| Current Provisions | $53,885 | $213,571 | $111,951 | $122,773 |
| Current Accrued Expenses | $1,104,126 | $1,226,314 | $949,594 | $846,974 |
| Dueto Related Parties Current | $0 | $1,047,550 | $5,203,762 | $8,695,702 |
| Net PPE | $355,209 | $564,693 | $1,268,264 | $1,590,889 |
| Accumulated Depreciation | $-2,589,592 | $-2,529,954 | $-1,977,943 | $-1,821,345 |
| Gross PPE | $2,944,801 | $3,094,647 | $3,246,207 | $3,412,234 |
| Leases | $1,559,764 | $1,560,897 | $1,641,060 | $1,777,820 |
| Other Properties | $143,325 | $144,048 | $151,445 | $164,066 |
| Machinery Furniture Equipment | $899,982 | $1,046,249 | $1,092,610 | $1,107,270 |
| Buildings And Improvements | $341,730 | $343,453 | $361,092 | $0 |
| Properties | $0 | $0 | $0 | $0 |
| Inventories Adjustments Allowances | $-56,414 | $-79,549 | $-158,834 | $-172,070 |
| Finished Goods | $448,668 | $553,682 | $446,866 | $584,747 |
| Raw Materials | $435,799 | $320,722 | $243,222 | $604,850 |
| Duefrom Related Parties Current | $417,563 | $0 | $58,381 | $15,581 |
| Construction In Progress | - | - | $0 | $363,078 |
Fetched: 2026-06-17
Cash Flow Statement (Annual)
| Metric | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-2,347,356 | $-1,935,116 | $-151,441 | $205,803 |
| Operating Activities | ||||
| Operating Cash Flow | $-2,345,333 | $-1,928,053 | $-80,757 | $268,293 |
| Cash Flow From Continuing Operating Activities | $-2,345,333 | $-1,928,053 | $-80,757 | $268,293 |
| Operating Gains Losses | $10,466 | - | - | - |
| Investing Activities | ||||
| Capital Expenditure | $-2,023 | $-7,063 | $-70,684 | $-62,490 |
| Investing Cash Flow | $63,516 | $26,423 | $-12,303 | $-46,909 |
| Cash Flow From Continuing Investing Activities | $63,516 | $26,423 | $-12,303 | $-46,909 |
| Net Other Investing Changes | - | $33,486 | $58,381 | $15,581 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $2,759,991 | $0 | $2,194,827 | $3,115,106 |
| Financing Cash Flow | $8,399,153 | $-2,624,428 | $2,941,602 | $1,595,140 |
| Cash Flow From Continuing Financing Activities | $8,399,153 | $-2,624,428 | $2,941,602 | $1,595,140 |
| Net Other Financing Charges | $5,704,277 | $-4,043,034 | $-3,258,203 | $-4,261,759 |
| Net Common Stock Issuance | $2,759,991 | $0 | $2,194,827 | $3,115,106 |
| Common Stock Issuance | $2,759,991 | $0 | $2,194,827 | $3,115,106 |
| Other | ||||
| Repayment Of Debt | $-1,918,118 | $-78,654 | $-26,106 | $-33,055 |
| Issuance Of Debt | $1,853,003 | $1,497,260 | $4,031,084 | $2,804,848 |
| Interest Paid Supplemental Data | $21,239 | $24,533 | $13,047 | $3,197 |
| End Cash Position | $18,129,432 | $12,077,187 | $17,368,478 | $15,569,619 |
| Beginning Cash Position | $12,077,187 | $17,368,478 | $15,569,619 | $13,358,975 |
| Effect Of Exchange Rate Changes | $-65,091 | $-765,233 | $-1,049,683 | $394,120 |
| Changes In Cash | $6,117,336 | $-4,526,058 | $2,848,542 | $1,816,524 |
| Net Issuance Payments Of Debt | $-65,115 | $1,418,606 | $4,004,978 | $2,771,793 |
| Net Long Term Debt Issuance | $-65,115 | $1,418,606 | $4,004,978 | $2,771,793 |
| Long Term Debt Payments | $-1,918,118 | $-78,654 | $-26,106 | $-33,055 |
| Long Term Debt Issuance | $1,853,003 | $1,497,260 | $4,031,084 | $2,804,848 |
| Net PPE Purchase And Sale | $63,516 | $-7,063 | $-70,684 | $-62,490 |
| Sale Of PPE | $65,539 | $0 | $0 | - |
| Purchase Of PPE | $-2,023 | $-7,063 | $-70,684 | $-62,490 |
| Change In Working Capital | $-971,735 | $-381,559 | $1,415,510 | $1,903,062 |
| Change In Other Working Capital | $-128,813 | $30,441 | $94,339 | $-186,399 |
| Change In Other Current Liabilities | $-228,845 | $38,064 | $-74,414 | $-360,860 |
| Change In Payables And Accrued Expense | $168,839 | $-81,527 | $-9,618 | $330,007 |
| Change In Accrued Expense | $298,762 | $-53,835 | $-46,373 | $384,799 |
| Change In Payable | $-129,923 | $-27,692 | $36,755 | $-54,792 |
| Change In Account Payable | $-114,081 | $-29,254 | $9,700 | $-22,792 |
| Change In Tax Payable | $-15,842 | $1,562 | $27,055 | $-32,000 |
| Change In Income Tax Payable | $-15,842 | $1,562 | $27,055 | $-32,000 |
| Change In Prepaid Assets | $-287,824 | $29,356 | $138 | $1,504,711 |
| Change In Inventory | $-14,530 | $-219,646 | $408,951 | $-180,797 |
| Change In Receivables | $-480,562 | $-178,247 | $996,114 | $796,400 |
| Changes In Account Receivables | $-257,085 | $-321,422 | $912,947 | $831,473 |
| Other Non Cash Items | $1,596,182 | $362,590 | $408,688 | $588,112 |
| Stock Based Compensation | $0 | $352,100 | $554,571 | $2,334,397 |
| Provisionand Write Offof Assets | $263,972 | $283,234 | $2,875,694 | $477,299 |
| Asset Impairment Charge | $-22,863 | $350,867 | $349,390 | $53,365 |
| Depreciation Amortization Depletion | $82,297 | $203,247 | $250,162 | $320,007 |
| Depreciation And Amortization | $82,297 | $203,247 | $250,162 | $320,007 |
| Amortization Cash Flow | $7,238 | $7,459 | - | - |
| Amortization Of Intangibles | $7,238 | $7,459 | - | - |
| Depreciation | $75,059 | $195,788 | - | - |
| Gain Loss On Sale Of PPE | $10,466 | $0 | $0 | - |
| Net Income From Continuing Operations | $-3,303,652 | $-3,098,532 | $-5,934,772 | $-5,736,095 |
| Income Tax Paid Supplemental Data | - | $0 | $0 | $16,733 |
| Proceeds From Stock Option Exercised | - | $0 | $0 | $-30,000 |
| Deferred Tax | - | $0 | $0 | $328,146 |
| Deferred Income Tax | - | $0 | $0 | $328,146 |
| Net Short Term Debt Issuance | - | - | $0 | $0 |
| Short Term Debt Payments | - | - | $0 | $0 |
| Short Term Debt Issuance | - | - | $3,721,667 | $2,804,848 |
| Net Investment Purchase And Sale | - | - | $0 | $0 |
| Purchase Of Investment | - | - | $0 | $0 |
| Net Intangibles Purchase And Sale | - | - | - | $0 |
| Purchase Of Intangibles | - | - | - | $0 |
| Gain Loss On Investment Securities | - | - | - | - |
Fetched: 2026-06-17